**Metabolic disposition of triazolam and clobazam in humanized CYP3A mice with a double knockout background of mouse *Cyp2c* and *Cyp3a* genes**

Kaoru Kobayashi, Genki Minegishi, Nina Kuriyama, Atsushi Miyajima, Satoshi Abe, Kanako Kazuki, Yasuhiro Kazuki

Drug Metabolism and Disposition
Manuscript Number: DMD-AR-2022-001087

Supplemental Table 1. AUC ratios of triazolam and its metabolites in WT, 3aKO and hCYP3A/3aKO mice.

| Metabolite/triazolam | WT | 3aKO | hCYP3A/3aKO |
|---|---|---|---|
| 1'-hydroxytriazolam/triazolam | 2.74 ± 0.789 | 0.528 ± 0.258** | 0.428 ± 0.061** |
| 4-hydroxytriazolam/triazolam | 0.325 ± 0.058 | 0.050 ± 0.007** | 0.086 ± 0.008** |

Data are expressed as means ± S. D. (n = 5/group).

Mice were given an oral dose of triazolam (2 mg/kg). Plasma concentrations of triazolam, 1'-hydroxytriazolam and 4-hydroxytriazolam were determined and area under the plasma concentration-time curve ($AUC_{0\text{-}120}$) from 0 to 120 min was calculated using the linear trapezoidal method. **$p<0.01$ compared with WT (one-way ANOVA with a post-hoc test of Scheffé's F test).